Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?

Giuseppe Sanguineti, Matthew L. Cavey, Eugene J. Endres, Paola Franzone, Salvina Barra, Brent Parker, Michela Marcenaro, Martin Colman, Stefano Agostinelli, Franca Foppiano, Vito Vitale

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Purpose: To compare late rectal toxicity rates after three-dimensional conformal radiotherapy to the prostate alone (P-3D-CRT) and whole-pelvis intensity-modulated radiotherapy along with a prostate boost (WP-IMRT/PB) to the same nominal total dose to the prostate. Patients and Methods: 68 patients treated with conformal radiotherapy to the prostate only to 76 Gy at the National Institute for Cancer Research, Genoa, Italy, represented the first group (P-3D-CRT). The second group consisted of 45 patients treated at the University of Texas Medical Branch (UTMB), Galveston, TX, USA, with IMRT covering the pelvic nodes and seminal vesicles to 54 Gy at 1.8 Gy per fraction and the prostate to 60 Gy in the same 30 fractions. A separate phase boosted the prostate to 76 Gy (WP-IMRT/PB). Major aspects of planning were remarkably similar at both institutions leaving the inclusion or not of pelvic nodes as the main treatment-related difference between the two groups. Late rectal toxicity was prospectively scored according to the RTOG scale. All patients have a 12-month minimum follow-up, and mean follow-up, similar in both groups, is 25.9 months (SD [standard deviation]: 8.4 months). Results: At 2 years, the estimated cumulative incidence of grade 2 late rectal toxicity is 6% ± 4% for WP-IMRT/PB and 21.2% ± 6% for P-3D-CRT (p = 0.06). The difference became significant (HR [hazard ratio] = 0.1, 95% CI [confidence interval]: 0.0-0.6; p = 0.01) at multivariate analysis. None of the patients developed grade 3+ toxicity. Conclusion: Despite the larger treated volume, WP-IMRT/PB allows more rectal sparing than P-3D-CRT.

Original languageEnglish (US)
Pages (from-to)543-549
Number of pages7
JournalStrahlentherapie und Onkologie
Volume182
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Prostate
Radiotherapy
Intensity-Modulated Radiotherapy
Pelvis
Conformal Radiotherapy
Therapeutics
National Cancer Institute (U.S.)
Seminal Vesicles
Italy
Multivariate Analysis
Confidence Intervals
Incidence
Research

Keywords

  • IMRT
  • Late rectal toxicity
  • Whole-pelvis radiotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cancer Research
  • Radiological and Ultrasound Technology

Cite this

Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy? / Sanguineti, Giuseppe; Cavey, Matthew L.; Endres, Eugene J.; Franzone, Paola; Barra, Salvina; Parker, Brent; Marcenaro, Michela; Colman, Martin; Agostinelli, Stefano; Foppiano, Franca; Vitale, Vito.

In: Strahlentherapie und Onkologie, Vol. 182, No. 9, 09.2006, p. 543-549.

Research output: Contribution to journalArticle

Sanguineti, G, Cavey, ML, Endres, EJ, Franzone, P, Barra, S, Parker, B, Marcenaro, M, Colman, M, Agostinelli, S, Foppiano, F & Vitale, V 2006, 'Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?', Strahlentherapie und Onkologie, vol. 182, no. 9, pp. 543-549. https://doi.org/10.1007/s00066-006-1586-9
Sanguineti, Giuseppe ; Cavey, Matthew L. ; Endres, Eugene J. ; Franzone, Paola ; Barra, Salvina ; Parker, Brent ; Marcenaro, Michela ; Colman, Martin ; Agostinelli, Stefano ; Foppiano, Franca ; Vitale, Vito. / Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?. In: Strahlentherapie und Onkologie. 2006 ; Vol. 182, No. 9. pp. 543-549.
@article{ad27963b0a524f82856549bce65c97c9,
title = "Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?",
abstract = "Purpose: To compare late rectal toxicity rates after three-dimensional conformal radiotherapy to the prostate alone (P-3D-CRT) and whole-pelvis intensity-modulated radiotherapy along with a prostate boost (WP-IMRT/PB) to the same nominal total dose to the prostate. Patients and Methods: 68 patients treated with conformal radiotherapy to the prostate only to 76 Gy at the National Institute for Cancer Research, Genoa, Italy, represented the first group (P-3D-CRT). The second group consisted of 45 patients treated at the University of Texas Medical Branch (UTMB), Galveston, TX, USA, with IMRT covering the pelvic nodes and seminal vesicles to 54 Gy at 1.8 Gy per fraction and the prostate to 60 Gy in the same 30 fractions. A separate phase boosted the prostate to 76 Gy (WP-IMRT/PB). Major aspects of planning were remarkably similar at both institutions leaving the inclusion or not of pelvic nodes as the main treatment-related difference between the two groups. Late rectal toxicity was prospectively scored according to the RTOG scale. All patients have a 12-month minimum follow-up, and mean follow-up, similar in both groups, is 25.9 months (SD [standard deviation]: 8.4 months). Results: At 2 years, the estimated cumulative incidence of grade 2 late rectal toxicity is 6{\%} ± 4{\%} for WP-IMRT/PB and 21.2{\%} ± 6{\%} for P-3D-CRT (p = 0.06). The difference became significant (HR [hazard ratio] = 0.1, 95{\%} CI [confidence interval]: 0.0-0.6; p = 0.01) at multivariate analysis. None of the patients developed grade 3+ toxicity. Conclusion: Despite the larger treated volume, WP-IMRT/PB allows more rectal sparing than P-3D-CRT.",
keywords = "IMRT, Late rectal toxicity, Whole-pelvis radiotherapy",
author = "Giuseppe Sanguineti and Cavey, {Matthew L.} and Endres, {Eugene J.} and Paola Franzone and Salvina Barra and Brent Parker and Michela Marcenaro and Martin Colman and Stefano Agostinelli and Franca Foppiano and Vito Vitale",
year = "2006",
month = "9",
doi = "10.1007/s00066-006-1586-9",
language = "English (US)",
volume = "182",
pages = "543--549",
journal = "Strahlentherapie und Onkologie",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "9",

}

TY - JOUR

T1 - Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?

AU - Sanguineti, Giuseppe

AU - Cavey, Matthew L.

AU - Endres, Eugene J.

AU - Franzone, Paola

AU - Barra, Salvina

AU - Parker, Brent

AU - Marcenaro, Michela

AU - Colman, Martin

AU - Agostinelli, Stefano

AU - Foppiano, Franca

AU - Vitale, Vito

PY - 2006/9

Y1 - 2006/9

N2 - Purpose: To compare late rectal toxicity rates after three-dimensional conformal radiotherapy to the prostate alone (P-3D-CRT) and whole-pelvis intensity-modulated radiotherapy along with a prostate boost (WP-IMRT/PB) to the same nominal total dose to the prostate. Patients and Methods: 68 patients treated with conformal radiotherapy to the prostate only to 76 Gy at the National Institute for Cancer Research, Genoa, Italy, represented the first group (P-3D-CRT). The second group consisted of 45 patients treated at the University of Texas Medical Branch (UTMB), Galveston, TX, USA, with IMRT covering the pelvic nodes and seminal vesicles to 54 Gy at 1.8 Gy per fraction and the prostate to 60 Gy in the same 30 fractions. A separate phase boosted the prostate to 76 Gy (WP-IMRT/PB). Major aspects of planning were remarkably similar at both institutions leaving the inclusion or not of pelvic nodes as the main treatment-related difference between the two groups. Late rectal toxicity was prospectively scored according to the RTOG scale. All patients have a 12-month minimum follow-up, and mean follow-up, similar in both groups, is 25.9 months (SD [standard deviation]: 8.4 months). Results: At 2 years, the estimated cumulative incidence of grade 2 late rectal toxicity is 6% ± 4% for WP-IMRT/PB and 21.2% ± 6% for P-3D-CRT (p = 0.06). The difference became significant (HR [hazard ratio] = 0.1, 95% CI [confidence interval]: 0.0-0.6; p = 0.01) at multivariate analysis. None of the patients developed grade 3+ toxicity. Conclusion: Despite the larger treated volume, WP-IMRT/PB allows more rectal sparing than P-3D-CRT.

AB - Purpose: To compare late rectal toxicity rates after three-dimensional conformal radiotherapy to the prostate alone (P-3D-CRT) and whole-pelvis intensity-modulated radiotherapy along with a prostate boost (WP-IMRT/PB) to the same nominal total dose to the prostate. Patients and Methods: 68 patients treated with conformal radiotherapy to the prostate only to 76 Gy at the National Institute for Cancer Research, Genoa, Italy, represented the first group (P-3D-CRT). The second group consisted of 45 patients treated at the University of Texas Medical Branch (UTMB), Galveston, TX, USA, with IMRT covering the pelvic nodes and seminal vesicles to 54 Gy at 1.8 Gy per fraction and the prostate to 60 Gy in the same 30 fractions. A separate phase boosted the prostate to 76 Gy (WP-IMRT/PB). Major aspects of planning were remarkably similar at both institutions leaving the inclusion or not of pelvic nodes as the main treatment-related difference between the two groups. Late rectal toxicity was prospectively scored according to the RTOG scale. All patients have a 12-month minimum follow-up, and mean follow-up, similar in both groups, is 25.9 months (SD [standard deviation]: 8.4 months). Results: At 2 years, the estimated cumulative incidence of grade 2 late rectal toxicity is 6% ± 4% for WP-IMRT/PB and 21.2% ± 6% for P-3D-CRT (p = 0.06). The difference became significant (HR [hazard ratio] = 0.1, 95% CI [confidence interval]: 0.0-0.6; p = 0.01) at multivariate analysis. None of the patients developed grade 3+ toxicity. Conclusion: Despite the larger treated volume, WP-IMRT/PB allows more rectal sparing than P-3D-CRT.

KW - IMRT

KW - Late rectal toxicity

KW - Whole-pelvis radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=33748143474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748143474&partnerID=8YFLogxK

U2 - 10.1007/s00066-006-1586-9

DO - 10.1007/s00066-006-1586-9

M3 - Article

VL - 182

SP - 543

EP - 549

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

SN - 0179-7158

IS - 9

ER -